Updates are available Correction dated 2024-06-17
Click to view Correction: https://doi.org/10.1038/s41443-024-00916-4
-
Authors
Perelman, Michael A. https://orcid.org/0000-0001-5372-8095
- License Information
-
More Information
Article History
Received: 1 February 2024
Revised: 9 March 2024
Accepted: 2 April 2024
First Online: 12 April 2024
Change Date: 17 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41443-024-00916-4
Competing interests
: The author is a member of the editorial board of IJIR: Your Sexual Medicine Journal. As disclosed in the first paragraph of this Comment, the author served previously as a consultant to a law firm that represented Merck & Co, Inc. (Propecia’s TM USA manufacturer) in matters regarding 5α-reductase inhibitors (5αri). The author attended the introductory “Ro Advisory Summit” in September 2019, and chose not to become an active advisor, but at the time of publication of this Comment remains listed as a “Medical Advisor” on their website.
Free to read: This content has been made available to all.
